AMP Final Rule: Your First Chance to Discuss the Application, Implementation, and Impact at MDRP

Medicaid Drug Rebate Program Summit 2016 is a platform to connect with 550+ MDRP executives and 100+ industry experts and deep dive into the most critical elements of the rule and provide you with instruction on how to manage them. Roll up your sleeves and work with colleagues to best embrace the adjustments you need to make.

Get a Front Row Seat Today and Participate LIVE at the Event!

Register Now to SAVE $200 off the Current Rate.
Use Code XP2158DRUG

See how MDRP 2016 will facilitate industry comments to CMS across all three days of the conference:

• Deconstructing the Average Manufacturer Price (AMP) Final Rule: A Step by Step Analysis of the Key Implications of the Final Rule—Celgene Corporation, Eli Lilly, & Amgen

• Identification & Alternate Rebate Formula for Line Extensions—Hogan Lovells US LLC

• Bundling—IMS Health

• 5 i AMP: Eligibility, Calculations & Implications—King & Spalding

• Retail Communities Pharmacies: Identification and Impact of The Final Rule—National Association of Chain Drug Stores (NACDS)

• Impact of The Final Rule on COT—Model N

• Service Fees: Bona Fide or Constructive Price Concessions—Hogan Lovells US LLP

• Revenue optimization: What Should Manufacturers be Doing in this Period of Change?

Download the Brochure Here for Full Agenda and Speaker Details

PLUS! Get 340B Updates directly from HRSA during the main conference from Krista M. Pedley, Director, Office of Pharmacy Affairs, HRSA and Michelle Herzog, Deputy Director, Office of Pharmacy Affairs, HRSA.

Register Now to SAVE $200 off the Current Rate! Use Code XP2158DRUG

This is your opportunity to benchmark best practices and gain solutions to overcome new operational challenges brought on by AMP Final Rule, 340B, Medicaid Expansion, Class of Trade, Fair Market Value, FSS, VA, OIG, and other critical government programs.

---

The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.